BCM
FULC icon

Burrage Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Burrage Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-319,819
Closed -$3.77M – 24
2021
Q1 		$3.77M Buy
319,819
+47,893
+18% +$592K 3.05% 15
2020
Q4 		$3.18M Sell
271,926
-19,719
-7% -$223K 2.43% 18
2020
Q3 		$2.31M Hold
291,645
– – 1.83% 21
2020
Q2 		$5.33M Buy
+291,645
New +$4.59M 3.73% 12

Other funds holding FULC

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Burrage Capital Management's FULC Position: Q2 2021 in Review

Burrage Capital Management sold out of Fulcrum Therapeutics (FULC) in Q2 2021, closing a stake of 319,819 shares — an estimated $3.77M sold.

Burrage Capital Management first reported a position in FULC in Q2 2020 and held it in 4 quarters. The position peaked at $5.33M in Q2 2020. 67 funds tracked by Wall St. Rank hold FULC as of Q2 2021.

  • Burrage Capital Management reported no remaining Fulcrum Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Burrage Capital Management sold 319,819 Fulcrum Therapeutics shares in Q2 2021, an estimated $3.77M.
  • Burrage Capital Management first reported a position in Fulcrum Therapeutics in Q2 2020 and held it in 4 quarters.
  • Burrage Capital Management's Fulcrum Therapeutics position peaked at $5.33M in Q2 2020.
  • 67 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2021.

Based on Burrage Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.